Kopran Ltd
Kopran Ltd Q4 FY26 Results & Presentation Highlights: Revenue, Margins & Order Book
Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Kopran Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q4 FY 2025-26 Revenue from Operations: Rs. EBITDA for Q4 FY 2025-26: Rs.
From Kopran Ltd's Q4 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY 2025-26 Revenue from Operations: Rs. 23,402 Lakhs
- Q4 FY 2024-25 Revenue from Operations: Rs. 17,236 Lakhs
- Year-on-year revenue growth (Q4 FY 2025-26 vs Q4 FY 2024-25): Rs. 6,166 Lakhs increase (~35.8% growth)
- Total Revenue FY 2025-26: Rs. 68,142 Lakhs (no prior year FY revenue for direct comparison on this page)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Kopran Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Focus on R&D to develop niche, high-value/high-volume APIs and intermediates (Page 15).
- Capacity expansion planned as a strategic imperative (Page 15).
- API and R&D facility located at Panoli (Gujarat) indicated as part of capacity expansion (Page 15).
- No specific capex amounts or timelines explicitly stated for capacity expansion or new plants/projects.
- Manufacturing facilities with global accreditations at existing locations in Maharashtra: API vertical at MIDC Mahad (11,900 sq. mts.) and formulations vertical at Khopoli (11,432 sq. mts.) (Pages 13-14).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Kopran Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹234 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Kopran Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key investor presentation takeaways from Anuh Pharma Ltd's Q4 FY26 investor presentation — and how i
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q4 FY26 inv
- Remus Pharmaceuticals Ltd (Q4 FY26)
Quarterly Revenue (H2-FY26):** INR 4,534 Mn, up 30.4% YoY from INR 3,478 Mn in H2-FY25 . Key investor presentation takeaways from Remus Pharmaceuticals Ltd's Q4
- Lincoln Pharmaceuticals Ltd (Q4 FY26)
EBITDA: ₹26 crore, a 3% year-on-year increase . Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how i
Frequently Asked Questions
What were Kopran Ltd Q4 FY26 results?
Q4 FY 2025-26 Revenue from Operations: Rs. EBITDA for Q4 FY 2025-26: Rs.
What is Kopran Ltd share price analysis?
Kopran Ltd currently shows a neutral. The stock trades at a P/E of 53.7 with a market cap of ₹1,342 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kopran Ltd planning capital expenditure?
Focus on R&D to develop niche, high-value/high-volume APIs and intermediates (Page 15). - Capacity expansion planned as a strategic imperative (Page 15). - API and R&D facility located at Panoli (Gujarat) indicated as part of capacity expansion (Page 15). - No specific capex amounts or timelines explicitly stated for capacity expansion or new plants/projects. - Manufacturing facilities with global accreditations at existing locations in Maharashtra: API vertical at MIDC Mahad (11,900 sq.
Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.